Equity investments in biotech companies fell 68% to $5.9 billion in the first half of 2008 compared to the first half of 2007, according to Recombinant Capital. The biggest decline was among public offerings, as only one biotech firm went public. Private offerings for public companies declined 76% to $2.8 billion, while offerings for private […]
Despite high prices and strong demand for many metals and minerals, mining companies are finding it harder to make new projects profitable. As a result, companies are delaying projects or closing mines. BHP Billiton, Perilya and Teck Cominco have all announced closures or plans to limit output of some mines. Soaring costs for energy, building […]
In its annual rankings of the world’s top universities, Shanghai Jiao Tong University has listed 17 US universities among the top 20 and 55 US universities among the top 100. Britain and Germany had the second greatest number of universities in the top 100 rankings with 10 and six, respectively. Japan, Canada and Sweden each […]
Patent-application filings rose 4.9% in 2006 to over 1.76 million due to more filings by China, Korea and the US, according to the World Intellectual Property Organization. China’s share of patent filings increased 32.1% to 7.3%, compared to shares of 6.6% and 6.7% for Korea and the US, respectively. Filings for drug patents rose 1.7%, […]
The FDA and prescription benefits manager Medco Health Solutions have entered into a two-year agreement to study pharmacogenomics. Using reports produced by Medco based on the pharmacy claims of its 60 million members, FDA will assess the use of genetic tests for prescribing drugs and determining drug safety, as well as how doctors utilize such […]
BASF and Dow hold the top two spots in this year’s Chemical & Engineering News survey of the top 50 chemical producers, with 2007 chemicals sales of $65.04 billion and $53.51 billion, an increase of 20% and 9%, respectively. The aggregate profit margin for the top 50 firms was 10.4%, up from last year’s 9.5%. […]
According to data gathered from the US clinical trials registry for phases II–IV studies between October 2005 and September 2007, six major therapeutic areas accounted for 68% of all protocols and 74% of all sites. In order from most to least activity, these six areas were oncology, central nervous system (CNS) disorders, cardiology, infectious diseases, […]
According to a report from the Centers for Disease Control’s Division of Laboratory Standards, over 200,000 Clinical Laboratory Improvement Amendments (CLIA)-certified labs conduct around 6.8 billion tests annually and account for 2.3% of healthcare funding. Total lab testing revenue was $52 billion for 2007, 54% of which was from hospital-based labs. Of the CLIA labs, […]
On a basic level, a workflow is a sequence of steps necessary to complete a designated task. In a laboratory, there are many workflows. For example, a workflow may consist of the specific procedures for preparing a sample for analysis. Another workflow may encompass sample preparation as well as sample analysis. Laboratory product and instrument […]
The 56th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics (ASMS) was held at the Denver, Colorado, convention center from June 1 to June 5. The ASMS meeting continued its trend of increasing attendance, which was up close to 2% to 6,569. The number of exhibitors dropped by 12 to 171 […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
